Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxypropyl betadex - ZyVersa Therapeutics

Next Previous
Drug Profile

Hydroxypropyl betadex - ZyVersa Therapeutics

Alternative Names: 2-hydroxypropyl-β-cyclodextrin - ZyVersa Therapeutics; 2HPβCD - ZyVersa Therapeutics; Cholesterol Efflux Mediator™; HPβCD - ZyVersa Therapeutics; Hydroxypropyl beta cyclodextrin - ZyVersa Therapeutics; VAR 200; VAR 200-01; VAR 200-02; VAR 200-03; VAR 300; VAR 400

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator L&F Research
  • Developer ZyVersa Therapeutics
  • Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I Focal segmental glomerulosclerosis
  • Preclinical Hereditary nephritis

Most Recent Events

  • 11 Jun 2025 Phase-II clinical trials in Diabetic nephropathies in USA (IV) (NCT06489340)
  • 12 May 2025 Hydroxypropyl betadex is still in preclinical trials for Hydroxypropyl betadex and Hereditary-nephritis in USA
  • 28 Apr 2025 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top